n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, March 21st, 2016

The QualityStocks
Daily Stock List

graphic
graphic

AppYea, Inc. (APYP)

SmallCapVoice, PennyPickAlerts, Fortune Stock Alerts, Stock Commander, PREPUMP STOCKS, Damn Good Penny Picks, Penny Stock Newsletter, Penny Picks, StockMister, Penny Stock Circle, and 1-2-3 Stock Alerts reported earlier on AppYea, Inc. (APYP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AppYea, Inc. is an international mobile application (app) developer for iOS, Google Play, and Amazon platforms. The Company involves in the acquisition, purchase, maintenance and creation of mobile software applications (apps). It operates its own titles and also provides strategic partnerships with promising mobile app developers. AppYea has obtained a number of portfolios. These include Disney/Universal Theme Park Wait Time Map Apps, Katsomoto Games & StreamMe.

AppYea has its corporate headquarters in Fort Worth, Texas. The Company’s shares trade on the OTC Markets Group’s OTCQB. AppYea was incorporated in the State of South Dakota on November 26, 2012.

The Company provides strategic partnerships for talented mobile app developers. These partnerships are a strategic part of its larger Mergers & Acquisitions (M&A) business development plan. AppYea offers complete buy outs, earn-outs, or strategic partnership agreements for one’s fully developed projects and scaled investment into undeveloped projects.

AppYea centers on a number of different categories. These include next-generation social networks and gaming. The Company engages in custom mobile app development for iPad application development; iPhone application development; Android application development; Blackberry application development, as well as Windows Mobile development.

AppYea announced in the autumn of 2015, the acquisition of 32 mobile applications. That new acquisition added to the Company’s diversified app holdings. The apps cover a broad array of niche segments across iOS, Android, Amazon, and Kindle. The theme across the portfolio is strategy guides, video & text based tutorials, and other helpful content for popular games.

In December of 2015, AppYea announced the recent acquisition of 60 mobile applications by way of an asset purchase agreement. The primary focus for this portfolio of apps is in the gaming apps arena.

AppYea has obtained revenue through the sale of its developed and acquired mobile applications and also through advertisement integration. Its present business plans include the marketing of its mobile applications, and the expansion of its mobile application portfolio through the acquisition of third party developed mobile applications and/or mobile applications development companies.

AppYea, Inc. (APYP), closed Monday's trading session at $0.0025, up 19.05%, on 19,077,300 volume with 494 trades. The average volume for the last 60 days is 2,462,206 and the stock's 52-week low/high is $0.0012/$1.03.

MassRoots, Inc. (MSRT)

CFN Media Group, Wealth Daily, Cannabis Financial Network News, and Equities.com reported recently on MassRoots, Inc. (MSRT), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Denver, Colorado-based MassRoots, Inc. is one of the largest and most active social networks for the cannabis community. Individuals use the Company’s app to find smoking friends, share their cannabis experiences, and stay connected with local dispensaries. MassRoots’ shares trade on the OTC Markets’ OTCQB. The Company is affiliated with the top organizations in the cannabis industry. These include the ArcView Group and the National Cannabis Industry Association.

MassRoots’ intention is on expanding to multiple states during 2016. Businesses can use the Company to advertise their goods and services to cannabis consumers. MassRoots starts adding in features, including order ahead, delivery, and the in-app purchase of ancillary products as regulations allow.

The Company has an estimated 300-plus dispensaries actively posting on its network. These include the nation's foremost dispensaries: Native Roots, MiNDFUL, The Clinic, BuddyBoyBrands, Green Solution, Good Chemistry, Denver Relief, Natural Remedies, as well as Harborside Health Center.

Furthermore, MassRoots is partnering and taking an equity position in a full seed-to-sale system. This system is now operating in stealth under the name Flowhub during private beta. The MassRoots and Flowhub development teams are integrating their systems, expanding the services available to MassRoots' users and dispensaries.

Last month, MassRoots announced it crossed 775,000 users on its network. The Company is expecting it will cross one million users shortly before April 20, 2016. The vast majority of the Company’s engagement and growth comes from its mobile applications. Nonetheless, MassRoots launched a new web platform in early December 2015 to open an additional revenue and user growth stream.

MassRoots’ Chief Executive Officer, Mr. Isaac Dietrich, stated, “The weeks leading up to 4/20 are the cannabis industry’s holiday season – a period where millions of cannabis enthusiasts make purchases, buy tickets, and make plans for marijuana’s official holiday. Historically, during the weeks leading up to 4/20, we have experienced significantly higher growth and visibility. This year, we expect the 4/20 season will propel our network to one million users and have a significant impact on our revenue growth.”

MassRoots, Inc. (MSRT), closed Monday's trading session at $1.05, even for the day, on 69,081 volume with 105 trades. The average volume for the last 60 days is 51,672 and the stock's 52-week low/high is $0.65/$7.01.

TapImmune, Inc. (TPIV)

Stock News Now, Pennybuster, Penny Stock Craze, Stock Preacher, InvestorSoup, Penny Stocks Finder, SuperStockTips, Beacon Equity Research, and Innovative Marketing reported recently on TapImmune, Inc. (TPIV), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

TapImmune, Inc. is a vaccine technologies company, which specializes in the development of innovative gene based immunotherapeutics and vaccines in the areas of oncology and infectious disease. The Company is developing TAP-based prophylactic vaccines commercially suitable for the prevention of infectious diseases and as Biodefense agents. TapImmune is developing cancer vaccines that combine the use of novel antigens together with its TAP expression technology. Its technology has all-inclusive applications in developing therapeutic and preventative vaccines.

TapImmune’s lead product candidates include peptide and nucleic acid-based vaccine technologies. The design of these technologies is to restore and/or augment antigen presentation and then recognition and killing of cancer cells by the immune system.    

TapImmune has developed a unique, cost effective, immunotherapeutic vaccine expression and delivery system. The novel platform is called TapImmune's PolyStart™ technology. The PolyStart and PAA (Peptide Antigen Array) technologies are straight forwardly and easily managed as a fast, adaptable, plugin-and-play system. This means they can be configured to produce peptides for any desired pathogen.

The Company’s PolyStart™ technology has been strategically designed to directly enhance the immune system's ability to stimulate either or both cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be associated with one, or any cancer, infectious disease, or bio-threat. The present emphasis of its PolyStart technology is on its cancer program (e.g., Her2/neu and folate receptor alpha antigens).

The gene based TAP technology, as a vaccine component, has the potential to improve the efficacy of prophylactic and immunotherapeutic vaccines considerably. This is because it addresses a fundamental mechanism for T cell recognition and response. Additionally, TAP expression has the unique ability to enhance the effector function of mature killer T cells. This enhancement of effector function is potentially complementary to any/all vaccine approaches designed to enhance cellular responses.

The Company’s vaccine is to be studied in a $13.3 Million U.S. Department of Defense grant to Mayo Clinic for a Phase II Clinical Trial in Triple Negative Breast Cancer. The trial will use the Folate Receptor Alpha Vaccine licensed to TapImmune for commercialization.

Last month, TapImmune announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application called, "A chimeric nucleic acid molecule with non-AUG initiation sequences." The patent claims are for TapImmune's proprietary PolyStart™ technology. The term of the patent extends to March 17, 2034. Its inventor is Dr. Robert Z. Florkiewicz, Head of Research at TapImmune. Furthermore, in February, TapImmune announced that the U.S. Food & Drug Administration (FDA) granted Fast Track Designation for the Company’s cancer vaccine TPIV 200 in the treatment of ovarian cancer.

TapImmune, Inc. (TPIV), closed Monday's trading session at $0.65, up 1.56%, on 214,073 volume with 103 trades. The average volume for the last 60 days is 299,413 and the stock's 52-week low/high is $0.165/$1.71.

Propanc Health Group Corp. (PPCH)

Ceocast News, Equities.com, PennyPro, PennyStocks24, Greenbackers, PennyStockRumors.net, and PricelessPennyStocks reported on Propanc Health Group Corp. (PPCH), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.

Propanc Health Group Corp. is an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, particularly those suffering from pancreatic, ovarian and colorectal cancers. Propanc has developed – in tandem with its scientific and oncology consultants - a rational, composite formulation of anti-cancer compounds that enable and support a variety of cancer treatment options. The Company’s leading products are variations upon its novel formulation and involve or employ proenzymes. These are inactive precursors of enzymes. Propanc Health Group is a development stage healthcare business.

The Company’s intention in the near term is to target patients with limited remaining therapeutic options for the treatment of solid tumors. This includes colorectal or pancreatic tumors. In the future, its plan is to develop its lead product to treat early stage cancer, pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic screening.   

Propanc’s leading products are PRP and PRP-DCM. These are novel, patented suppository formulations based on proteolytic proenzymes that are inactive precursors of enzymes. PRP is a novel, patented, once daily suppository formulation of proteolytic proenzymes. Regarding PRP-DCM, work undertaken by Propanc has centered on maximizing the potential of PRP as a drug suitable for long term maintenance. Scientific research has concentrated on developing a novel combination of anti-cancer agents working in combination with proteolytic proenzymes that enhance PRP’s anti-cancer effects.

Many preclinical activities are underway for the Company’s lead product, PRP.  Animal efficacy studies in a number of tumor cell lines are underway for PRP with Propanc’s research partner, vivoPharm, in Hershey, Pennsylvania. In addition, the Company has chosen pancreatic cancer as its lead indication for human studies. Propanc Management will seek Orphan Drug Designation for PRP for this indication in each jurisdiction.

Today, Propanc Health Group announced it received $1.2 million from an institutional investor. This is to fast track its preclinical activities, including GMP (Good Manufacturing Practice) manufacturing and preparation for future patient trials that it hopes to file an application for in 2016.

Propanc Health Group Corp. (PPCH), closed Monday's trading session at $0.0285, up 7.55%, on 20,468,329 volume with 823 trades. The average volume for the last 60 days is 8,691,651 and the stock's 52-week low/high is $0.01/$0.1338.

Anpulo Food, Inc. (ANPFF)

PennyPickAlerts, Fortune Stock Alerts, SMS Penny Picks, eliteotc.com, Wall Street Beauties, WINNINGOTC, SmallCapAllStars, TryBestPennyStocks.biz, Value Penny Stocks, Jet-Life Penny Stocks, HotStockProfits, Equity Observer, Penny Stock Newsletter, Penny Picks, Damn Good Penny Picks, and PREPUMP STOCKS reported this month on Anpulo Food, Inc. (ANPFF), and we do as well, here at the QualityStocks Daily Newsletter.

Based in Laifeng, the People’s Republic of China (PRC), Anpulo Food, Inc. processes, distributes and markets pork and cured pork products in the PRC. Together with its subsidiaries, the Company offers chilled pork, frozen pork, and prepared meats, and also hog by-products and various meats under the Anpulo and Linghaotuzhu brands. Anpulo Food’s shares trade on the OTC Markets Group’s OTCQB.

Anpulo Foodbuys live hogs from pig farms or individual farmers in Laifeng County and its neighboring region in the PRC for slaughtering, processing and curing.The Company markets its products mainly to supermarkets, meat distributors, warehouse club stores, food retailers, foodservice distributors, restaurant operators, hotel chains, schools, healthcare facilities, the military, as well as other food processors via its dealers, agents, and wholesalers.

Anpulo Food uses the "No. Zero" hog, the Nationally Approved Brand of ecologically bred pig. Anpulo’s dedication is to product safety and customers' health as its priority. The Company works to keep producing products of premier quality from organic and ecologically fed pork. Its successful model attracts many buyers from numerous first and second tier cities in the PRC. The Company’s product line (as of December 31, 2014) included in excess of 190 unique meat products.
 
Anpulo Food’s intention is to acquire a number of regional slaughterhouses and meat processing plants this year. This is to grow its expected annual slaughter capacity to 250,000 hogs. These acquisitions would guarantee the Company added fresh meat resources. It would allow Anpulo Food to increase overall market share.

The Company in the coming year will continue to develop partnerships with international supermarket behemoths such as Carrefour, and also local large supermarkets to increase sales channels.  Furthermore, Anpulo’s intention is to build more retail regional stores this year.  Moreover, the Company’s intention is to strengthen risk management within every business link. This includes meat quality control and pork illness control.

Anpulo Food, Inc. (ANPFF), closed Monday's trading session at $1.55, up 29.17%, on 74,470 volume with 159 trades. The average volume for the last 60 days is 2,452 and the stock's 52-week low/high is $0.60/$3.90.

graphic

The QualityStocks
Company Corner

graphic
graphic

Oakridge Global Energy Solutions, Inc. (OGES)

The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.6489, up 6.38%, on 35,673 volume with 39 trades. The stock’s average daily volume over the past 60 days is 27,097, and its 52-week low/high is $0.20/$2.40.

Oakridge Global Energy Solutions, Inc. is excited, in this revenue guidance announcement for Q1, FY2016, to announce the first ever commercial revenues in the history of the Company. Oakridge Global Energy Solutions has fully completed its transition, begun in July 1, 2014 and continued through to December 31, 2015, from a Research and Development company to a fully-fledged “Made in USA”, lithium ion battery manufacturing company. After spending more than $40M USD in research, product development and corporate restructuring since the Company’s major shareholder, Precept Fund Management SPC took control of the company in mid-2013, Oakridge kicked off 2016 in full commercial production ramp up mode.

Oakridge Global Energy Solutions, Inc. (OGES) is an integrated energy storage solutions company focused on the design, development and manufacture of high-quality cells, batteries and power systems. The company's innovative 'Made in the U.S.A.' product line includes multiple lithium-ion technologies and form factors that are optimized to address three high-demand target markets – including stationary and grid storage; motive applications, such as electric and hybrid electric fleet vehicles; and specialty applications, such as military, aerospace, marine, medical and telecom backup.

Through a recent restructuring of its operations, Oakridge strategically positioned itself to expand its market reach moving forward. The company currently owns and operates two manufacturing facilities in Melbourne, Florida, which play an instrumental role in its efforts to meet the growing demand for its cutting-edge large format Pro Series golf car batteries and its small format Patriot Series RC batteries. These operations also allow Oakridge to bring stable employment opportunities back to the U.S., effectively highlighting its tireless commitment to the revitalization of the country's manufacturing industry.

The company also maintains a presence on the international stage through its recently formed subsidiary, Oakridge Global Energy Solutions Limited, Hong Kong. This subsidiary, which is expected to serve as the foundation for Oakridge's sales efforts throughout the Asia-Pacific region, was created primarily to address the tremendous international demand for its revolutionary stored energy solutions. The company also maintains a substantial interest in Leclanche S.A., a Swiss developer and manufacturer of large-sized lithium-ion batteries that was originally founded in 1909.

Oakridge has indicated plans to expand its presence in a collection of markets throughout Europe and Asia as it continues to build upon its established product development and manufacturing infrastructure. The company will lean on the expertise of its proven management team – which includes well over a century of combined industry experience – as it looks to increase its share of the $12 billion domestic battery manufacturing industry. Disclaimer

Oakridge Global Energy Solutions, Inc. Company Blog

Oakridge Global Energy Solutions, Inc. News:

Revenue Guidance Q1 FY2016 First Commercial Revenues in the Company’s History

Oakridge Global Energy Solutions Investor Conference Call - Tuesday March 22

Oakridge Announces Strategic Business Alliance Agreement with Major Japanese Trading House

Nutra Pharma Corp. (NPHC)

The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.0219, up 36.88%, on 159,868 volume with 13 trades. The stock’s average daily volume over the past 60 days is 507,995, and its 52-week low/high is $0.0025/$0.27.

Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.

The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.

Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer

Nutra Pharma Corp. Company Blog

Nutra Pharma Corp. News:

Nutra Pharma to Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016

Nutra Pharma Announces Management Expansion and Business Updates

Nutra Pharma Corp.’s (NPHC) 7-year Marketing Exclusivity for Pediatric MS RPI-78M is more than just Luck

View Systems, Inc. (VSYM)

The QualityStocks Daily Newsletter would like to spotlight View Systems, Inc. (VSYM). Today, View Systems, Inc. closed trading at $0.0016, up 6.67%, on 20,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 532,967, and its 52-week low/high is $0.0011/$0.013.

View Systems, Inc. (VSYM) is a leading security technology products company with “state-of-the-art” technological solutions for modern security problems. Targeting the challenging business opportunities in the opening decades of the 21st century and beyond, View Systems has solutions for law enforcement facilities such as correctional institutions as well as other government agencies, schools, courthouses, event and sports venues, the military and commercial businesses.

The senior management team is comprised of successful businessmen with decades of business and professional experience in the security industry. The approach used by View Systems utilizes the expertise of this team to provide innovative solutions to security problems with reliable “cutting edge” products in conjunction with client-oriented security consulting services.

The company’s flagship product, ViewScan, is an advanced walk-through Concealed Weapons Detection System (CWD) that greatly simplifies the process of discriminating suspicious items from harmless ones. The highly sensitive, completely passive sensor technology powering the system accurately detects the location and number of threat objects such as knives, guns and razor blades while ignoring personal artifacts like coins, keys and belt buckles. A portable version of this system has only a fifteen minute setup time using only a screwdriver and it easily fits inside a golf size case.

Experts say the security industry has been the fastest-growing sector of the global economy during the past decade. Today, it is conservatively estimated to be a $100 billion-a-year industry and growing. As the business environment continues to get more complex, especially in foreign markets, View Systems is strategically positioned to capitalize on unsurpassed opportunity. Disclaimer

View Systems, Inc. Company Blog

View Systems, Inc. News:

View Systems, Inc. (VSYM) to Acquire Y.M. Advantage, Inc.

View Systems in Discussions With Three M&A Candidates and Reviewing Letter of Intent

View Systems, Inc. Files for Patent, Begins Manufacturing of Enhanced ViewScan Product

Giggles N' Hugs, Inc. (GIGL)

The QualityStocks Daily Newsletter would like to spotlight Giggles N' Hugs, Inc. (GIGL). Today, Giggles N' Hugs, Inc. closed trading at $0.0888, up 11.00%, on 5,276 volume with 2 trades. The stock’s average daily volume over the past 60 days is 39,185, and its 52-week low/high is $0.0137/$0.2999.

Los Angeles-based Giggles N' Hugs, Inc. (GIGL) is a first-of-its-kind, award-winning family restaurant and play space that combines organic gourmet food with the play elements for children in a 2500-square-foot play space in the middle of the restaurant. The concept is similar to Chuck E. Cheese, but offers a unique healthier, high-end version for health conscious parents and families. Parents eat and relax while the kids have an incredible time playing in the custom-made play area with giant climbers, dragons, castles, pirate ships slides and swings and a multitude of other toys.

In addition to nightly shows and concerts, every 30 minutes Giggles N' Hugs provides an activity such as face painting, disco dance parties, karaoke, games, arts and crafts, and much more. Giggles N' Hugs has been voted the No. 1 family restaurant, No. 1 birthday party place, and the No. 1 indoor play space in all of Los Angeles, and has attracted a star-studded list of customers including Sandra Bullock, Heidi Klum, Jessica Alba, Halle Berry, Jennifer Garner and Ben Affleck, Denis Quaid, Mark Whalberg, Adam Sandler, Dustin Hoffman and many more.

Revenue is derived from several sources, including food and beverage sales, beer and wine, birthday parties (40%), admission and membership fees to play, along with retail sales. These revenue-generating locations are also highly sought-after tenants. The company currently has three locations in the top premier malls around Los Angeles; four of the largest mall owners in the country are giving Giggles N' Hugs up to 75% discounts on rent and providing upward of $700,000 of upfront cash for each location to get Giggles N' Hugs into their malls around the country.

Growth and recognition of this caliber are driven by a very powerful management team. Giggles N' Hugs President John Kaufman was the COO at California Pizza Kitchen when the founders had just two locations. Joined by Giggles N' Hugs' CFO Phillip Gay, who at the time was CFO of California Kitchen, Kaufman grew the company from two to more than 100 locations – at which time it was bought by Pepsi Co. Kaufman was recruited as president of Koo Koo Roo Chicken, one of the fastest growing fast-casual concepts on the west coast, while Gay joined Wolfgang Puck Restaurants group as CFO, eventually becoming the CEO.

Giggles N' Hugs was founded as a truly "kid friendly" establishment catered specifically to the size, interests, and nutrition needs of children. Since opening its first Giggles N' Hugs in 2009, the company has received a steady stream of interest from more than 300 interested parties looking to expand the concept – via franchise or master licenses – in the U.S. as well globally in countries such as Germany, England, Dubai, Russia, Colombia, Australia , Singapore, Turkey, among the many more. Disclaimer

Giggles N' Hugs, Inc. Company Blog

Giggles N' Hugs, Inc. News:

Giggles N' Hugs, Inc. (GIGL) CEO Discusses 2016 Growth Strategies in Second QualityStocks Interview

Giggles N’ Hugs Signs Agreement with New York-Based Chardan Capital Markets

Giggles N Hugs to present at the 8th annual LD Micro Conference main event

FlexWeek (FXWK)

The QualityStocks Daily Newsletter would like to spotlight FlexWeek (FXWK). Today, FlexWeek closed trading at $0.55, even for the day. The stock’s average daily volume over the past 60 days is 223, and its 52-week low/high is $0.075/$1.15.

FlexWeek (FXWK) is a pioneer in the global peer-to-peer (P2P) marketplace with the introduction of a unique platform that allows timeshare owners to discover, book and offer unused vacation time directly to the public and other timeshare owners. This approach eliminates the need for timeshare owners to use costly trading platforms such as Interval International or RCI, while potentially reducing unused timeshare inventory.

FlexWeek's P2P website (www.FlexWeek.com) and mobile application is similar to AirBNB's $20 billion approach to the travel industry, but is the first and only P2P marketplace exclusive to fractional vacation ownerships. FlexWeek differs from the existing model, where timeshare weeks must be "banked" with a trading company such as Interval International or RCI, and instead charges the booking fees to the renter of the vacation time, eliminating the cost to the private timeshare owner.

The FlexWeek platform also addresses another specific industry challenge. The average timeshare is only booked 79% of the year, according to the American Resort Development Association's 2012 research survey. Whether or not a privately owned timeshare unit is used, the owner still has to pay annual maintenance fees, and most owners end up losing thousands of dollars in wasted paid-for vacation time over their ownership period. With FlexWeek, an owner of unused paid vacation time can now offer their specific booked week for rent directly to the FlexWeek marketplace to recoup cost or even make a profit on the rental. The glut of unused timeshare inventory allows a potential renter to stay in a very nice condo for a fraction of what they would pay in hotel fees making it a win-win for both the owner and the renter of the vacation time.

Led by founder Kristopher Chavez, who has more than 10 years of experience operating businesses that acquire, rent, sell and transfer timeshares internationally, FlexWeek's management team will leverage its collective expertise to facilitate the company's direction and growth in this new market. FlexWeek's leadership has founded rapidly growing sales organizations generating 8-figure revenues within a year's time, and has experience scaling other models to financial success and/or acquisition rapidly with limited investment. Disclaimer

FlexWeek Company Blog

FlexWeek News:

FlexWeek, Inc. (FXWK): Stay in Vacation Homes around the World for Less than the Cost of Hotels

FlexWeek, Inc. (FXWK) Announces Engagement of QualityStocks Corporate Communications Suite

FlexWeek, Inc. (FXWK) is “One to Watch”

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Profitable Trader Authority
(GRSO)

2.

QualityStocks
(NPHC)

3.

Damn Good Penny Picks
(INCT)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251